See more : Suryoday Small Finance Bank Limited (SURYODAY.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Kindred Biosciences, Inc. (KIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kindred Biosciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- MGC Pharmaceuticals Limited (MXC.AX) Income Statement Analysis – Financial Results
- Rosseti Kuban PJSC (KUBE.ME) Income Statement Analysis – Financial Results
- Galenica AG (GALE.SW) Income Statement Analysis – Financial Results
- Sainik Finance & Industries Limited (SAINIK.BO) Income Statement Analysis – Financial Results
- Dream International Limited (1126.HK) Income Statement Analysis – Financial Results
Kindred Biosciences, Inc. (KIN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: http://www.kindredbio.com
About Kindred Biosciences, Inc.
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.16M | 4.26M | 1.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.63M | 587.00K | 324.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 37.54M | 3.67M | 1.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 89.03% | 86.21% | 83.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.28M | 28.31M | 26.40M | 17.67M | 13.86M | 19.41M | 18.69M | 3.14M | 75.00K |
| General & Administrative | 21.98M | 37.93M | 22.08M | 11.90M | 6.84M | 6.86M | 8.54M | 1.08M | 45.00K |
| Selling & Marketing | 0.00 | 0.00 | 4.42M | 2.08M | 1.47M | 992.00K | 0.00 | 0.00 | 0.00 |
| SG&A | 21.98M | 37.93M | 26.50M | 13.99M | 8.31M | 7.85M | 8.54M | 1.08M | 45.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 53.26M | 66.24M | 52.90M | 31.65M | 22.17M | 27.26M | 27.23M | 4.22M | 120.00K |
| Cost & Expenses | 57.89M | 66.82M | 53.22M | 31.65M | 22.17M | 27.26M | 27.23M | 4.22M | 120.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00 | 0.00 |
| Depreciation & Amortization | 4.68M | 2.54M | 805.00K | 475.00K | 155.00K | 146.00K | 58.00K | 3.13K | 0.00 |
| EBITDA | -15.29M | -58.85M | -48.89M | -30.40M | -22.34M | -26.98M | -27.08M | -4.21M | -120.00K |
| EBITDA Ratio | -36.27% | -1,382.75% | -2,486.52% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.97M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Operating Income Ratio | -47.36% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -56.00 | 0.00 |
| Income Before Tax | -21.80M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Income Before Tax Ratio | -51.69% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00 | 0.00 |
| Net Income | -23.62M | -61.39M | -49.69M | -30.88M | -22.50M | -27.13M | -27.14M | -4.21M | -120.00K |
| Net Income Ratio | -56.03% | -1,442.41% | -2,527.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.60 | -1.59 | -1.60 | -1.23 | -1.13 | -1.37 | -1.44 | -1.13 | -0.03 |
| EPS Diluted | -0.60 | -1.59 | -1.60 | -1.23 | -1.13 | -1.37 | -1.44 | -1.13 | -0.03 |
| Weighted Avg Shares Out | 39.29M | 38.66M | 31.00M | 25.08M | 19.87M | 19.77M | 18.78M | 3.73M | 4.71M |
| Weighted Avg Shares Out (Dil) | 39.29M | 38.66M | 31.00M | 25.08M | 19.87M | 19.77M | 18.78M | 3.73M | 4.71M |
Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates
Kindred Bio (KIN) delivered earnings and revenue surprises of 15.15% and -0.94%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Kindred Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results
SAN FRANCISCO, March 16, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided updates...
Kindred Biosciences (KIN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kindred Biosciences Announces Submission of Parvovirus Monoclonal Antibody Data for Prophylactic Indication
SAN FRANCISCO, Feb. 25, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has submitted efficacy data to support the prophylactic indication for KIND-030 to...
Kindred Biosciences Announces Two New Appointments to Board of Directors
SAN FRANCISCO, Feb. 9, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor,...
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel Disease
SAN FRANCISCO, Dec. 21, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness study of its monoclonal antibody against tumour...
Elanco Announces Agreement with KindredBio to Bring First-of-its-Kind Canine Parvovirus Therapy to Market
GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced an agreement with Kindred Biosciences (NASDAQ: KIN) to acquire exclusive global rights to KIND-030, a first-of-its-kind monoclonal antibody being developed for the treatment and prevention of canine parvovirus (CPV). This...
Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q3 2020 Results - Earnings Call Transcript
Kindred Biosciences, Inc. (KIN) CEO Richard Chin on Q3 2020 Results - Earnings Call Transcript
Riassunto: Il Project Management Institute lancia i prodotti iniziali della prima suite di risorse del settore indipendente dalla piattaforma per accelerare l'adozione su larga scala del 'citizen development'
Il Project Management Institute (PMI), la più importante associazione professionale a carattere internazionale per la gestione dei progetti, oggi ha p
Riassunto: Raiffeisen Banking Group e il partner di tecnologia bancaria SDS annunciano piani di collaborazione futura
Il Raiffeisen Banking Group e SDS annunciano la firma di un accordo di collaborazione pluriennale. L'austriaco Raiffeisen Banking Group è il più grand
Source: https://incomestatements.info
Category: Stock Reports